A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G

Open source

DOI: 10.14309/ctg.0000000000000056
Published: 2019 Jul
Container: Clinical and translational gastroenterology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.14309/ctg.0000000000000056,
  title = {A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.},
  author = {Kelley RK and Gane E and Assenat E and Siebler J and Galle PR and Merle P and Hourmand IO and Cleverly A and Zhao Y and Gueorguieva I and Lahn M and Faivre S and Benhadji KA and Giannelli G},
  year = {2019},
  journal = {Clinical and translational gastroenterology},
  doi = {10.14309/ctg.0000000000000056},
  url = {https://doi.org/10.14309/ctg.0000000000000056}
}

RIS

TY  - JOUR
TI  - A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
AU  - Kelley RK
AU  - Gane E
AU  - Assenat E
AU  - Siebler J
AU  - Galle PR
AU  - Merle P
AU  - Hourmand IO
AU  - Cleverly A
AU  - Zhao Y
AU  - Gueorguieva I
AU  - Lahn M
AU  - Faivre S
AU  - Benhadji KA
AU  - Giannelli G
PY  - 2019
JO  - Clinical and translational gastroenterology
DO  - 10.14309/ctg.0000000000000056
UR  - https://doi.org/10.14309/ctg.0000000000000056
ER  -

APA

RK, K., E, G., E, A., J, S., PR, G., P, M., IO, H., A, C., Y, Z., I, G., M, L., S, F., KA, B., & G, G. (2019). A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.. Clinical and translational gastroenterology. https://doi.org/10.14309/ctg.0000000000000056

Source records

pubmed · retrieved 2026-09-26T00:18:10.160Z